Cas 154087-05-5,5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide

154087-05-5

Post Buying Request

Basic information

Product Name: 5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide
Synonyms: 5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide
CAS NO:154087-05-5
Molecular Formula:
Molecular Weight: 528.782
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide(CAS DataBase Reference)
NIST Chemistry Reference: 5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide(154087-05-5)
EPA Substance Registry System: 5-benzamido-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide(154087-05-5)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 154087-05-5(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

154087-05-5 Suppliers

Recommended suppliers

154087-05-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 154087-05-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,0,8 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 154087-05:
(8*1)+(7*5)+(6*4)+(5*0)+(4*8)+(3*7)+(2*0)+(1*5)=125
125 % 10 = 5
So 154087-05-5 is a valid CAS Registry Number.

154087-05-5Upstream product

154087-05-5Downstream Products

154087-05-5Relevant academic research and scientific papers

Discovery of novel triazole compounds as selective IL-1β releasement inhibitors

Chen, Leyuan,Gou, Wenfeng,Hou, Wenbin,Li, Yiliang,Mu, Ruixu,Wei, Huiqiang,Ye, Caiying,Yu, Jingcheng,Zhou, Yongting,Zhu, Lei

supporting information, (2021/10/27)

Inflammation and immunity are closely related to the occurrence and development of a variety of immune diseases. Although IL-1β has been identified as a key cytokine in many immune diseases, safe and specific small molecular IL-1β releasement inhibitors a

Inflamsome nucleotide binding oligomerization domain-like receptor protein 3 inhibitor as well as preparation method and application thereof

-

Paragraph 0112-0114; 0151-0153, (2021/11/03)

The invention discloses compounds which are shown in a formula I and can inhibit secretion of inflammasome nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) and secretion of interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), and a preparation method of the compound. ELISA experiments show that the compounds can significantly inhibit the activity of NLRP3 and reduce the expression of NLRP3 downstream inflammatory factors IL-1beta. A further experiment shows that part of the compounds have a selective inhibition effect on IL-1beta/TNF-alpha. The compounds shown in the formula I are expected to become novel anti-inflammatory drugs and autoimmune disease treatment drugs.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 154087-05-5